Drug Profile
Research programme: p53 reactivators - Biogen
Alternative Names: p53 modulators - BiogenLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Reata Pharmaceuticals
- Developer Biogen
- Class Small molecules
- Mechanism of Action Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer